Antios Therapeutics’ $96 Million Series B Financing

Dechert advised Antios Therapeutics on the deal.Antios Therapeutics, Inc. (“Antios”) completed its $96 million Series B financing.   Antios is a clinical-stage biopharmaceutical company focused on the development…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now